Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lido-Touch is a 5% lidocaine transdermal patch developed by Sparsha Pharma International, an Indian pharmaceutical company specializing in transdermal drug delivery systems. Launched in 2022, the product utilizes advanced transdermal matrix technology to provide sustained 24-hour delivery of lidocaine, offering a more efficient alternative to traditional hydrogel patches. Its mechanism of action involves the reversible blockade of voltage-gated sodium channels (Nav) in neuronal membranes, which inhibits the initiation and conduction of nerve impulses. This results in local anesthesia and analgesia, making it particularly effective for managing localized pain conditions such as post-herpetic neuralgia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lido-Touch.